Subscribe to RSS
DOI: 10.1055/a-1953-0255
Der interventionelle Vorhofohrverschluss: eine Alternative zur oralen Antikoagulation
Interventional Left Atrial Appendage Closure: an Alternative to Oral AnticoagulationZusammenfassung
Die orale Antikoagulation ist der Standard zur Prävention von Embolien bei Patienten mit Vorhofflimmern. Der interventionelle Vorhofohrverschluss ist eine Alternative zur oralen Antikoagulation bei Patienten mit Vorhofflimmern und Kontraindikationen oder Unverträglichkeiten einer oralen Antikoagulation, insbesondere bei klinisch relevanten Blutungen. Die Sicherheit des Verfahrens hat in den letzten Jahren erheblich zugenommen. Mehrere große randomisierte Studien vergleichen aktuell die Effektivität und Sicherheit der oralen Antikoagulation und des interventionellen Vorhofohrverschlusses.
Abstract
Oral anticoagulation is the current standard for preventing thromboembolism in patients with atrial fibrillation. Interventional left atrial appendage closure is an alternative to oral anticoagulation in patients with atrial fibrillation with contraindications to an oral anticoagulation, in particular after clinically relevant bleeding. The safety of the procedure has increased significantly over the last decade. Large randomized trials are currently investigating the efficacy and safety of oral anticoagulation and interventional closure of the left atrial appendage.
Die orale Antikoagulation ist derzeit der Standard zur Prävention von Thromboembolien bei Vorhofflimmern.
Der interventionelle Vorhofohrverschluss ist eine Alternative zur oralen Antikoagulation bei Kontraindikationen oder Unverträglichkeiten einer oralen Antikoagulation, insbesondere nach klinisch relevanten Blutungen.
Die Sicherheit und Durchführbarkeit des Verfahrens sind in den letzten Jahren deutlich verbessert worden.
Große Studien vergleichen aktuell die Sicherheit und Effektivität einer oralen Antikoagulation mit dem interventionellen Vorhofohrverschluss.
Schlüsselwörter
interventioneller Vorhofohrverschluss - orale Antikoagulation - Prävention - Embolien - KontraindikationenKeywords
oral anticoagulation - thromboembolism - contraindication - prevention - interventional left atrial appendage closurePublication History
Article published online:
05 December 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498 DOI: 10.1093/eurheartj/ehaa612. (PMID: 32860505)
- 2 Salmasi S, Loewen P, Tandun R. et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open 2020; 10: e034778 DOI: 10.1136/bmjopen-2019-034778. (PMID: 32273316)
- 3 Omran H, Tsikas A, Sievert H. et al. A history of left atrial appendage occlusion with the PLAATO device. Interven Cardiol Clinics 2018; 7: 137-142
- 4 Freeman J, Varosy P, Price M. et al. The NCDR Left Atrial AppendageOcclusion Registry. J Am Coll Cardiol 2020; 75: 1503-1518 DOI: 10.1016/j.jacc.2019.12.040. (PMID: 32238316)
- 5 Reddy V, Sievert H, Halperin J. et al. Percutaneous left atrial appendage closure vs Warfarin for atrial fibrillation. A randomized trial. JAMA 2014; 312: 1988-1998 DOI: 10.1001/jama.2014.15192. (PMID: 25399274)
- 6 Osmancik P, Herman D, Neuzil P. et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol 2020; 75: 3122-3135 DOI: 10.1016/j.jacc.2020.04.067. (PMID: 32586585)
- 7 Freeman JV, Varosy P, Price MJ. et al. The NCDR Left Atrial Appendage Occlusion Registry. J Am Coll Cardiol 2020; 75: 1503-1518 DOI: 10.1016/j.jacc.2019.12.040. (PMID: 32238316)
- 8 Hildick-Smith D, Landmesser U, Camm A. et al. Left atrial appendage occlusion with the AmplatzerTM AmuletTM device: full results of the prospective global observational study. Eur Heart J 2020; 41: 2894-2901 DOI: 10.1093/eurheartj/ehaa169. (PMID: 32243499)
- 9 Galea R, De Marco F, Meneveau N. et al. Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. Circulation 2022; 145: 724-738 DOI: 10.1161/CIRCULATIONAHA.121.057859. (PMID: 34747186)
- 10 Lakkireddy D, Thaler D, Ellis C. et al. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE). Circulation 2021; 144: 1543-1552 DOI: 10.1161/CIRCULATIONAHA.121.057063. (PMID: 34459659)
- 11 Kar S, Doshi S, Sadu A. et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device Results from the PINNACLE FLX Trial. Circulation 2021; 143: 1754-1762
- 12 Lakkireddy D, Thaler D, Ellis C. et al. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE). Circulation 2021; 144: 1543-1552 DOI: 10.1161/CIRCULATIONAHA.121.057063. (PMID: 34459659)
- 13 Dukkipati S, Kar S, Holmes D. et al. Device related thrombus aufter left atrial appendage closure. Incidence, Predictors, and Outcome. Circulation 2018; 138: 874-885 DOI: 10.1161/CIRCULATIONAHA.118.035090. (PMID: 29752398)
- 14 Sedaghat A, Vij V, Al-Kassou B. et al. Device related thrombus after left atrial appendage closure. Data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ Cardiovasc Interv 2021; 14: 544-553 DOI: 10.1161/CIRCINTERVENTIONS.120.010195. (PMID: 34003661)
- 15 Flores-Umanzor E, Cepas-Guillen P, Arzamendi D. et al. Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban ADALA study. J Interv Card Electrophysiol 2020; 59: 471-477 DOI: 10.1007/s10840-020-00884-x. (PMID: 32986176)
- 16 Holmes D, Reddy V, Buchbinder M. et al. The assessment of Watchman device in patients unsuitable for oral anticoagulation ASAP TOO trial. Am Heart J 2017; 189: 68-74 DOI: 10.1016/j.ahj.2017.03.007. (PMID: 28625383)
- 17 Wazni O, Boersma L, Heleay J. et al. Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation: Rationale and Design of the OPTION randomized trial. Am Heart J 2022; 251: 35-42 DOI: 10.1016/j.ahj.2022.05.003. (PMID: 35526570)